5
Managing the Toxicity Profile and the "Prednisone Factor" 15:58 Jackson: We’ve talked a lot about efficacy, but as future clinicians, the "price" of that efficacy—the toxicity—is where the rubber meets the road. For abiraterone, the safety profile is essentially a lesson in endocrinology. Because you’re inhibiting CYP17, you’re hitting the adrenals. The Phase 2 LACOG study showed that Grade 3 or 4 adverse events occurred in about 31% of the abiraterone arm.
16:25 Miles: Right, and the specific "abiraterone flavors" of toxicity are hypertension and hypokalemia. In that same study, hypertension was seen in 21% of patients. And let’s not forget the long-term metabolic effects of the required prednisone. You’re looking at risks of hyperglycemia—seen in about 10% of patients—and potential bone mineral density loss over time. It’s a metabolic management task for the physician.
16:50 Jackson: Now, let’s flip to apalutamide. In the LACOG study, the Grade 3-4 adverse event rate was actually lower—21.4%. But the "flavor" is different. The big one for apalutamide is rash. We’re talking about 26% of patients in some cohorts experiencing a rash, and in about 12%, it was Grade 3 or 4. That’s a significant dermatological issue that can lead to treatment interruption or discontinuation.
17:18 Miles: And then there’s fatigue. Fatigue was reported in about 21% of apalutamide patients in that Phase 2 trial. For a patient who’s already dealing with the systemic effects of metastatic cancer and ADT, adding significant drug-induced fatigue can really impact quality of life. Interestingly, in the LACOG study, the "Functional Assessment of Cancer Therapy-Prostate"—FACT-P scores—were actually quite similar across the arms, suggesting that patients "tolerate" these different side effect profiles about the same in terms of overall quality of life.
17:47 Jackson: But here’s a nuance for the students: the "Central Nervous System" effects. Because apalutamide is an androgen receptor antagonist that can cross the blood-brain barrier—albeit at low levels—there’s always been a concern about seizures. In the early trials, that was a major talking point. However, in the real-world data, the incidence of seizures is extremely low. What we see more of are things like "cognitive and attention disorders" or memory impairment. One study in non-metastatic CRPC patients found CNS-related adverse events in about 9% of apalutamide patients.
18:23 Miles: It’s a trade-off. Do you want to manage a patient’s blood pressure, potassium, and blood sugar—the abiraterone/prednisone route—or do you want to manage their skin, their energy levels, and potential cognitive "fog"—the apalutamide route? For a patient with pre-existing poorly controlled diabetes or heart failure, apalutamide might look a lot safer because you avoid the mineralocorticoid excess and the steroids.
18:47 Jackson: On the other hand, for a patient with a history of falls or baseline cognitive decline, you might be more cautious with the AR antagonists. Speaking of falls, apalutamide has been associated with an increased risk of falls and fractures in the TITAN trial. It’s something to watch for, especially in the elderly population we’re treating.
19:05 Miles: And we have to consider drug-drug interactions, too. This is where it gets really technical. A 2024 study in "Expert Review of Anticancer Therapy" looked at "potential drug-drug interactions"—pDDIs. They found that 58% of patients on apalutamide had at least one pDDI, and four of those were "Grade X"—meaning "avoid combination." Abiraterone also has significant interactions because it’s a CYP2D6 inhibitor, which can mess with the metabolism of everything from beta-blockers to antidepressants.
19:36 Jackson: It’s a polypharmacy nightmare. Most of these patients are on cardiovascular meds, CNS meds, or anti-infectives. If you’re prescribing apalutamide, you have to be very careful with drugs that are metabolized by CYP3A4, CYP2C19, or CYP2C9, because apalutamide is a potent inducer. You could end up lowering the plasma concentration of the patient’s other vital medications to sub-therapeutic levels.
20:06 Miles: That’s a huge takeaway. The "simplicity" of a one-pill-a-day regimen like apalutamide is slightly offset by the complexity of the "interaction map." Abiraterone is more complex because of the prednisone and the mineralocorticoid monitoring, but its interaction profile is different. As a med student on rounds, if you see a patient on one of these, your first job is to pull up their med list and check for those CYP interactions.
20:31 Jackson: And let’s not forget treatment discontinuation. In the real-world studies, about 8% to 10% of patients discontinue apalutamide due to adverse events, with rash being a leading cause. For abiraterone, the rates are similar, but the reasons are often related to "unacceptable side effects" like severe hypertension or the complications of long-term steroid use. It’s about finding the "least worst" set of side effects for that specific individual.
20:58 Miles: I think the LACOG data summarizes it well: both are effective, both have manageable toxicities, but the "management burden" for the clinician is different. Abiraterone is about the adrenals and metabolism; apalutamide is about the skin, the CNS, and the interaction profile.